131 related articles for article (PubMed ID: 17202116)
1. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
2. Routine Bone Imaging for Metastatic Renal Cell Carcinoma: Is it Time?
Parikh M
J Kidney Cancer VHL; 2021; 8(4):20-21. PubMed ID: 34722127
[No Abstract] [Full Text] [Related]
3. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
[TBL] [Abstract][Full Text] [Related]
4. Exploring the anticancer potential of hydrogen sulfide and BAY‑876 on clear cell renal cell carcinoma cells: Uncovering novel mutations in VHL and KDR genes among ccRCC patients.
Hamadamin PS; Maulood KA
Mol Clin Oncol; 2024 Mar; 20(3):21. PubMed ID: 38332991
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.
Anakha J; Dobariya P; Sharma SS; Pande AH
Med Oncol; 2023 Dec; 41(1):24. PubMed ID: 38123873
[TBL] [Abstract][Full Text] [Related]
6. Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series.
Liguori L; Luciano A; Polcaro G; Ottaiano A; Cascella M; Perri F; Pepe S; Sabbatino F
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38001973
[TBL] [Abstract][Full Text] [Related]
7. Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies.
Xiao J; Liang J; Zhang W; Li Y
Exp Ther Med; 2020 Sep; 20(3):1961-1966. PubMed ID: 32782505
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Drug-induced Thyroid Dysfunction.
Bhattacharya S; Goyal A; Kaur P; Singh R; Kalra S
Eur Endocrinol; 2020 Apr; 16(1):32-39. PubMed ID: 32595767
[TBL] [Abstract][Full Text] [Related]
9. Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer.
Palermo A; Napolitano A; Maggi D; Naciu AM; Tabacco G; Manfrini S; Crescenzi A; Taffon C; Pantano F; Vincenzi B; Tonini G; Santini D
Eur Thyroid J; 2020 May; 9(3):157-161. PubMed ID: 32523892
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent.
Jiang Z; Wang L; Liu X; Chen C; Wang B; Wang W; Hu C; Yu K; Qi Z; Liu Q; Wang A; Liu J; Hong G; Wang W; Liu Q
Acta Pharm Sin B; 2020 Mar; 10(3):488-497. PubMed ID: 32140394
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.
D'Aniello C; Berretta M; Cavaliere C; Rossetti S; Facchini BA; Iovane G; Mollo G; Capasso M; Pepa CD; Pesce L; D'Errico D; Buonerba C; Di Lorenzo G; Pisconti S; De Vita F; Facchini G
Front Oncol; 2019; 9():1400. PubMed ID: 31921657
[TBL] [Abstract][Full Text] [Related]
12. Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma.
Rizza L; Sbardella E; Gianfrilli D; Lauretta R; Tenuta M; Del Bene G; Longo F; Faggiano A; Lenzi A; Giannetta E; Pozza C
Endocrine; 2020 Mar; 67(3):597-604. PubMed ID: 31679139
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
[TBL] [Abstract][Full Text] [Related]
14. Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer.
Vasileiadis T; Chrisofos M; Safioleas M; Kontzoglou K; Papazisis K; Sdrolia A
BMC Cancer; 2019 Apr; 19(1):407. PubMed ID: 31039771
[TBL] [Abstract][Full Text] [Related]
15. Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies.
Krashin E; Piekiełko-Witkowska A; Ellis M; Ashur-Fabian O
Front Endocrinol (Lausanne); 2019; 10():59. PubMed ID: 30814976
[TBL] [Abstract][Full Text] [Related]
16. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
[TBL] [Abstract][Full Text] [Related]
17. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
Li J; Wang M; Zhang B; Wu X; Lin TL; Liu XF; Zhou Y; Zhang XH; Xu H; Shen LJ; Zou J; Lu P; Zhang D; Gu WJ; Zhang MX; Pan J; Cao H;
World J Gastroenterol; 2018 Dec; 24(46):5189-5202. PubMed ID: 30581268
[TBL] [Abstract][Full Text] [Related]
18. Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation.
Zhang N; Jin W; Zhou S; Yang JD; Harmsen WS; Giama NH; Wongjarupong N; Heimbach JK; Watt KD; Malhi H; Therneau TM; Roberts LR
Cancer Med; 2018 Dec; 7(12):5870-5878. PubMed ID: 30453389
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer.
Gurunathan S; Kang MH; Qasim M; Kim JH
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347840
[TBL] [Abstract][Full Text] [Related]
20. Effects of Toceranib Phosphate on the Hypothalamic-Pituitary-Thyroid Axis in Tumor-Bearing Dogs.
Hume KR; Rizzo VL; Cawley JR; Balkman CE
J Vet Intern Med; 2018 Jan; 32(1):377-383. PubMed ID: 29193327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
